Geode Capital Management LLC Increases Stock Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)

Geode Capital Management LLC lifted its holdings in shares of Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 14.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,269,664 shares of the company's stock after buying an additional 283,419 shares during the period. Geode Capital Management LLC owned approximately 1.49% of Wave Life Sciences worth $18,615,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. grew its position in shares of Wave Life Sciences by 209.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 844,617 shares of the company's stock worth $6,926,000 after purchasing an additional 571,345 shares in the last quarter. FMR LLC grew its position in Wave Life Sciences by 174.5% in the third quarter. FMR LLC now owns 1,540,190 shares of the company's stock worth $12,630,000 after acquiring an additional 979,110 shares in the last quarter. Maven Securities LTD bought a new stake in Wave Life Sciences in the third quarter worth $6,970,000. Privium Fund Management B.V. purchased a new position in shares of Wave Life Sciences during the 3rd quarter worth about $400,000. Finally, Moody Aldrich Partners LLC boosted its position in shares of Wave Life Sciences by 69.0% during the third quarter. Moody Aldrich Partners LLC now owns 303,062 shares of the company's stock valued at $2,485,000 after buying an additional 123,703 shares during the period. 89.73% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

WVE has been the topic of several research reports. Wells Fargo & Company raised their price objective on Wave Life Sciences from $11.00 to $22.00 and gave the stock an "overweight" rating in a report on Wednesday, October 16th. B. Riley boosted their price target on Wave Life Sciences from $19.00 to $22.00 and gave the company a "buy" rating in a report on Monday, November 4th. Mizuho increased their target price on shares of Wave Life Sciences from $19.00 to $22.00 and gave the stock an "outperform" rating in a research note on Thursday, November 21st. Leerink Partners boosted their price objective on Wave Life Sciences from $20.00 to $22.00 and gave the company an "outperform" rating in a research report on Wednesday, October 16th. Finally, JPMorgan Chase & Co. upped their price target on shares of Wave Life Sciences from $13.00 to $17.00 and gave the stock an "overweight" rating in a research report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $22.22.

Insider Buying and Selling

In related news, CEO Paul Bolno sold 51,234 shares of Wave Life Sciences stock in a transaction on Friday, November 15th. The shares were sold at an average price of $14.32, for a total value of $733,670.88. Following the transaction, the chief executive officer now directly owns 217,351 shares in the company, valued at $3,112,466.32. This trade represents a 19.08 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Chris Francis sold 208,836 shares of the stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $13.67, for a total transaction of $2,854,788.12. The disclosure for this sale can be found here. Insiders have sold a total of 436,544 shares of company stock valued at $6,271,569 in the last ninety days. Company insiders own 29.10% of the company's stock.

Wave Life Sciences Stock Down 4.3 %

NASDAQ:WVE traded down $0.58 on Friday, reaching $12.90. 595,165 shares of the company's stock were exchanged, compared to its average volume of 1,110,006. The firm has a market capitalization of $1.97 billion, a price-to-earnings ratio of -11.62 and a beta of -1.21. Wave Life Sciences Ltd. has a 52-week low of $3.50 and a 52-week high of $16.74. The business has a fifty day moving average of $14.41 and a 200-day moving average of $9.27.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.